股本结构
单位：万股
| 公告日期 | 2019-04-01 | 2019-04-01 | 2018-11-08 | 2018-11-08 | 2018-08-06 | 2018-08-06 |
|---|---|---|---|---|---|---|
| 证券总股本 | 6388.00 | 4820.62 | 4611.98 | 4596.71 | 4520.94 | 4501.21 |
| 普通股本 | 6388.00 | 4820.62 | 4611.98 | 4596.71 | 4520.94 | 4501.21 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2019-03-25 | 2018-12-31 | 2018-11-01 | 2018-09-30 | 2018-08-01 | 2018-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2019-04-01 | 6388.00 | 未披露 |
更多>>
On February 15, 2019, the Company entered into an underwriting agreement with H.C. Wainwright & Co., LLC related to the public offering by the Company of (i) 15,000,000 shares of the Company’s common stock , (ii) Series A warrants to purchase up to 15,000,000 shares of common stock and (iii) Series B warrants to purchase up to 15,000,000 shares of common stock.
|
2019-03-25 |
| 2019-04-01 | 4820.62 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock under stock plans
Issuance of common stock under ATM
Issuance of common stock under ESPP
Repurchase of contingently redeemable common stock
|
2018-12-31 |
| 2018-11-08 | 4611.98 | 未披露 | 定期报告 | 2018-11-01 |
| 2018-11-08 | 4596.71 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-06 | 4520.94 | 未披露 | 定期报告 | 2018-08-01 |
| 2018-08-06 | 4501.21 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-07 | 4479.63 | 未披露 | 定期报告 | 2018-05-02 |
| 2018-05-07 | 4479.16 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-02-27 | 4472.54 | 未披露 | 定期报告 | 2018-02-23 |
| 2018-02-27 | 4251.50 | 未披露 |
更多>>
From December 31, 2016 To December 31, 2017
Issuance of contingently redeemable common stock under private placement
Issuance of common stock under stock plans
Issuance of common stock under ESPP
Issuance of common stock upon an underwritten public offering, net of issuance costs
Issuance of common stock upon exercise of warrants
|
2017-12-31 |
| 2017-11-08 | 4239.36 | 未披露 | 定期报告 | 2017-11-02 |
| 2017-11-08 | 4236.09 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-08 | 4223.33 | 未披露 | 定期报告 | 2017-08-02 |
| 2017-08-08 | 4223.21 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-08 | 3585.37 | 未披露 | 定期报告 | 2017-05-03 |
| 2017-04-26 | 3584.80 | 未披露 | 定期报告 | 2017-04-17 |
| 2017-05-08 | 3584.63 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-05-08 | 3578.16 | 未披露 | 定期报告 | 2017-03-01 |
| 2017-03-14 | 3563.81 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock under "at-the-market"equity offering sales agreement, less issuance costs
Issuance of common stock under stock plans
Issuance of common stock under ESPP
Issuance of common stock upon an underwritten public offering, net of issuance costs
Issuance of common stock upon sale of common stock under the private placement, net of issuance costs
Issuance of common stock upon exercise of warrants
|
2016-12-31 |
| 2016-11-07 | 2745.14 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-08 | 2667.97 | 未披露 | 定期报告 | 2016-08-02 |
| 2016-08-08 | 2654.80 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-06-24 | 2647.06 | 未披露 |
更多>>
On June 1, 2016, we entered into a Securities Purchase Agreement with the selling stockholders, pursuant to which we sold in a private placement transaction an aggregate of 7,999,996 shares of our common stock and issued warrants to purchase up to 1,999,999 shares of our common stock.
|
2016-06-03 |
| 2016-05-05 | 1840.86 | 未披露 | 定期报告 | 2016-04-29 |
| 2016-05-05 | 1840.85 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-15 | 1839.52 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs
Issuance of common stock under stock plans
Issuance of common stock under ESPP
|
2015-12-31 |
| 2015-11-05 | 1835.56 | 未披露 | 定期报告 | 2015-11-03 |
| 2015-11-05 | 1835.50 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-10 | 1811.55 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-11 | 1804.99 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-16 | 1803.00 | 未披露 | 定期报告 | 2015-03-02 |
| 2015-03-16 | 1790.71 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Conversion of preferred stock to common stock upon initial public offering
Issuance of common stock upon initial public offering, net of issuance costs
Issuance of common stock upon exercise of warrant
Issuance of common stock under stock plans
Issuance of common stock under ESPP
Reflects a 1-for-11 reverse stock split of our capital stock that was effected on March 10, 2014
|
2014-12-31 |
| 2014-11-10 | 1775.79 | 未披露 | 定期报告 | 2014-10-31 |
| 2014-11-10 | 1772.78 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-11 | 1771.00 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-12 | 1768.06 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-12 | 1678.06 | 未披露 |
更多>>
Reflects a 1-for-11 reverse stock split of our capital stock that was effected on March 10, 2014
Reflects the conversion immediately prior to the completion of this offering of all of our outstanding shares of convertible preferred stock into an aggregate of 10,386,894 shares of common stock
|
2014-03-12 |
| 2014-03-10 | 39.28 | 979.63 |
更多>>
In February 2014, the Company’s board of directors and stockholders approved an amended and restated certificate of incorporation to effect a reverse split of shares of our common stock and convertible preferred stock at a 1-for-11 ratio. The reverse split became effective on March 10, 2014
|
2014-03-11 |
| 2014-02-12 | 432.15 | 10776.01 |
更多>>
from December 31, 2012 to December 31, 2013
Sale of shares of Series D convertible preferred stock, net of issuance costs of $158
Issuance of shares of Series D convertible preferred stock in exchange for convertible notes and interest payable to related parties
Issuance of shares of Series D convertible preferred stock upon conversion of the related-party loan payable to The Wellcome Trust
Issuance of common stock under stock plan
|
2013-12-31 |
| 2014-01-24 | 432.15 | 9858.58 |
更多>>
from December 31, 2012 to September 30, 2013
Sale of shares of Series D convertible preferred stock, net of issuance costs of $148 (unaudited)
Issuance of shares of Series D convertible preferred stock in exchange for convertible notes and interest payable to related parties (unaudited)
Issuance of shares of Series D convertible preferred stock upon conversion of the related-party loan payable to The Wellcome Trust (unaudited)
Issuance of common stock under stock plan (unaudited)
|
2013-09-30 |
On February 15, 2019, the Company entered into an underwriting agreement with H.C. Wainwright & Co., LLC related to the public offering by the Company of (i) 15,000,000 shares of the Company’s common stock , (ii) Series A warrants to purchase up to 15,000,000 shares of common stock and (iii) Series B warrants to purchase up to 15,000,000 shares of common stock.
from December 31, 2017 to December 31, 2018
Issuance of common stock under stock plans
Issuance of common stock under ATM
Issuance of common stock under ESPP
Repurchase of contingently redeemable common stock
From December 31, 2016 To December 31, 2017
Issuance of contingently redeemable common stock under private placement
Issuance of common stock under stock plans
Issuance of common stock under ESPP
Issuance of common stock upon an underwritten public offering, net of issuance costs
Issuance of common stock upon exercise of warrants
From December 31, 2015 to December 31, 2016
Issuance of common stock under "at-the-market"equity offering sales agreement, less issuance costs
Issuance of common stock under stock plans
Issuance of common stock under ESPP
Issuance of common stock upon an underwritten public offering, net of issuance costs
Issuance of common stock upon sale of common stock under the private placement, net of issuance costs
Issuance of common stock upon exercise of warrants
On June 1, 2016, we entered into a Securities Purchase Agreement with the selling stockholders, pursuant to which we sold in a private placement transaction an aggregate of 7,999,996 shares of our common stock and issued warrants to purchase up to 1,999,999 shares of our common stock.
From December 31, 2014 to December 31, 2015
Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs
Issuance of common stock under stock plans
Issuance of common stock under ESPP
from December 31, 2013 to December 31, 2014
Conversion of preferred stock to common stock upon initial public offering
Issuance of common stock upon initial public offering, net of issuance costs
Issuance of common stock upon exercise of warrant
Issuance of common stock under stock plans
Issuance of common stock under ESPP
Reflects a 1-for-11 reverse stock split of our capital stock that was effected on March 10, 2014
Reflects a 1-for-11 reverse stock split of our capital stock that was effected on March 10, 2014
Reflects the conversion immediately prior to the completion of this offering of all of our outstanding shares of convertible preferred stock into an aggregate of 10,386,894 shares of common stock
In February 2014, the Company’s board of directors and stockholders approved an amended and restated certificate of incorporation to effect a reverse split of shares of our common stock and convertible preferred stock at a 1-for-11 ratio. The reverse split became effective on March 10, 2014
from December 31, 2012 to December 31, 2013
Sale of shares of Series D convertible preferred stock, net of issuance costs of $158
Issuance of shares of Series D convertible preferred stock in exchange for convertible notes and interest payable to related parties
Issuance of shares of Series D convertible preferred stock upon conversion of the related-party loan payable to The Wellcome Trust
Issuance of common stock under stock plan
from December 31, 2012 to September 30, 2013
Sale of shares of Series D convertible preferred stock, net of issuance costs of $148 (unaudited)
Issuance of shares of Series D convertible preferred stock in exchange for convertible notes and interest payable to related parties (unaudited)
Issuance of shares of Series D convertible preferred stock upon conversion of the related-party loan payable to The Wellcome Trust (unaudited)
Issuance of common stock under stock plan (unaudited)